Sign in

Maja Pataki

Research Analyst at Kepler

Maja Pataki is Head of the Medical Devices Sector and Deputy Head of Swiss Research at Kepler Cheuvreux, specializing in equity research on medical technology and healthcare companies. She covers prominent firms such as Alcon and bioMérieux, frequently issuing recommendations and target prices; her recent performance metrics show a 33% success rate and an average return of -13.4% on rated stocks over the past year. Pataki began her analyst career at UBS from 1998 to 2011 before joining Kepler Cheuvreux in January 2012, building extensive sector expertise. She holds a degree from the University of Basel and is recognized for her deep analytical insights within the European medtech investment community.

Maja Pataki's questions to GNNDY leadership

Question · Q3 2023

Asked about the expected growth drivers for the enterprise market once it recovers, how the DKK 600 million in cost synergies relate to the 20% EBITA margin target for Hearing, and the reason for the growth slowdown in the Emerging Hearing business.

Answer

Long-term enterprise growth drivers like hybrid work remain intact, though the recovery timeline is uncertain. The announced synergies will support and increase the likelihood of achieving the 20% core Hearing margin target. The Emerging business (JabraEnhance.com) is growing according to plan, up 37% year-to-date, and is on track to reach profitability goals by late 2025 or early 2026.

Ask follow-up questions

Get Instant Answers from SEC Filings & Earnings Calls

Ask complex financial questions and get precise answers in seconds. Fintool scans millions of documents to surface insights beyond timely human analysis.

Search across 8,000+ companies
Access millions of SEC filings & transcripts
Get answers cited to the source
Try Fintool for Free

Trusted by leading investment firms and analysts